Summary of HR 1796: Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025

Purpose and Intent

The Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025 aims to enhance the understanding, prevention, and treatment of sickle cell disease and other heritable blood disorders. The bill seeks to improve research efforts, establish better surveillance systems, and promote effective treatment options for affected individuals.

Key Provisions

While the full text of the bill has not been provided, the title indicates several key areas of focus:

• Research: The bill is expected to allocate funding and resources for research initiatives aimed at understanding the genetic and environmental factors contributing to sickle cell disease and other blood disorders.

• Surveillance: It aims to establish comprehensive surveillance systems to monitor the prevalence and impact of these disorders, which will help in formulating public health strategies.

• Prevention: The legislation may include provisions for preventive measures, including education and awareness campaigns to inform communities about these disorders.

• Treatment: The bill is likely to promote the development and accessibility of effective treatment options, ensuring that patients receive the necessary care and support.

Affected Parties

The following groups are expected to be impacted by this legislation:

• Patients: Individuals diagnosed with sickle cell disease and other heritable blood disorders will benefit from improved research, treatment options, and preventive measures.

• Healthcare Providers: Medical professionals and institutions involved in the treatment and management of these conditions will receive guidance and support through enhanced research and resources.

• Researchers: Scientists and researchers focusing on blood disorders will gain access to funding and collaborative opportunities to advance their work.

• Public Health Officials: Those involved in public health will have better data and tools to address the needs of affected populations.

Legislative Actions and Timeline

• Introduced: March 3, 2025
• Referred to Committee: The bill was referred to the House Committee on Energy and Commerce on the same day it was introduced.

Sponsors

The bill is sponsored by:
- John James (Primary Sponsor)
- Troy A. Carter (Cosponsor)
- Danny K. Davis (Cosponsor)
- Marc A. Veasey (Cosponsor)

Related Bills

HR 1796 has several companion bills that may address similar issues:
- HR 1768
- S 735
- S 891

Conclusion

The Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025 represents a significant step towards improving the lives of those affected by sickle cell disease and other blood disorders. By focusing on research, surveillance, prevention, and treatment, the bill aims to create a comprehensive framework to address these critical health issues.